Compare NICE Ltd (NICE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Sanofi SA — how do they compare? NICE Ltd trades at $116.94 (market cap $6.81B), while Sanofi SA trades at $40.11 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 14× NICE Ltd's market cap, and Sanofi SA pays a 6.01% dividend while NICE Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold NICE Ltd for 15 Days and Sanofi SA for 94 Days on average.
| NICE | SNY | |
|---|---|---|
Market Cap | $6.81B | $95.18B |
Volume | 382,395 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $137.68 | $52.34 |
52-Week Low | $83.15 | $39.51 |
Typical Hold Time | 15 Days | 94 Days |
Enterprise Value | $6.54B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE trades at $116.83, up 0.35% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong Q2 2026 earnings, beating EPS estimates with $2.70 actual versus $2.63 expected, and was recently named a leader in the IDC MarketScape for contact center platforms (Business Wire, 2026-10-01). Revenue for 2025 was $2.95 billion with a net income margin of 20.78%.
The outlook is positive, supported by AI-driven growth and a reasonable valuation with a P/E of 17.08. However, risks include margin compression from increased investment and potential market volatility. Analyst sentiment is bullish with 12 buy ratings and no sells, but investors should monitor execution on AI initiatives and competitive pressures in the CX software space.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
